Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic-Reference-Cited by-同舟云学术

Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic

Published:2024-01-11 Issue:1 Volume:31 Page:436-446
ISSN:1718-7729
Container-title:Current Oncology
language:en
Short-container-title:Current Oncology

Author:

Bloom Julie R.¹,Rodriguez-Russo Carlos¹,Hsieh Kristin¹^ORCID,Dickstein Daniel R.¹,Sheu Ren-Dih¹,Jain Mayuri²,Moshier Erin²^ORCID,Liu Jerry¹,Gupta Vishal¹,Kirke Diana N.³,Roof Scott³,Misiukiewicz Krzysztof⁴,Posner Marshall⁴⁵,Bakst Richard¹,Sindhu Kunal K.¹^ORCID,Sharma Sonam⁶

Affiliation:

1. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

2. Department of Population Health Science and Policy, Tisch Cancer Institute Biostatistics Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

3. Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

4. Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

5. Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY 10029, USA

6. Department of Radiation Oncology, Summit Health, Berkeley Heights, NJ 07922, USA

Abstract

The COVID-19 pandemic precipitated drastic changes in cancer care. Its impact on the U.S. head and neck cancer population has yet to be fully understood. This study aims to understand the impact of pandemic-related changes on the head and neck cancer population. An observational study of head and neck cancer patients at a single institution during the spring of 2020 and 2019 was performed. Clinical characteristics and survival outcomes were analyzed. In 2020, 54 head and neck cancer patients were evaluated in the department of radiation oncology vs. 74 patients seen in 2019; 42% of the patients were female in 2019 versus 24% in 2020 (p = 0.036). The median follow-up time was 19.4 and 31 months for 2020 and 2019, respectively. After adjusting for stage, the relapse-free survival probability at 6 and 12 months was 79% and 69% in 2020 vs. 96% and 89% in 2019, respectively (p = 0.036). There was no significant difference in the overall survival, with 94% and 89% in 2020 and 2019, respectively (p = 0.61). Twenty-one percent of patients received induction chemotherapy in 2020 versus 5% in 2019 (p = 0.011); significantly more treatment incompletions occurred in 2020, 9% vs. 0% in 2019 (p = 0.012). Moreover, the stage-adjusted RFS differed between cohorts, suggesting head and neck cancer patients seen during the initial wave of COVID-19 may experience worse oncologic outcomes.

Publisher

MDPI AG

Link

https://www.mdpi.com/1718-7729/31/1/29/pdf

Reference42 articles.

1. (2022, November 11). COVID-19: Recommendations for Management of Elective Surgical Procedures. ACS. Available online: https://www.facs.org/for-medical-professionals/covid-19/clinical-guidance/elective-surgery/.

2. (2022, November 11). Centers for Medicare & Medicaid Services. CMS Adult Elective Surgery and Procedures Recommendations. 7 April 2020. p. 2, Available online: https://www.cms.gov/files/document/covid-elective-surgery-recommendations.pdf.

3. Impact of the COVID-19 pandemic on cancer incidence and mortality;Wells;Lancet Public Health,2022

4. (2022, November 11). Survey: COVID-19 Affecting Patients’ Access to Cancer Care. American Cancer Society Cancer Action Network. Available online: https://www.fightcancer.org/releases/survey-covid-19-affecting-patients%E2%80%99-access-cancer-care.

5. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: An international consensus;Mehanna;Lancet Oncol.,2020